<DOC>
	<DOCNO>NCT02814175</DOCNO>
	<brief_summary>An interventional Phase 4 open-label , randomize , control , parallel-group , multi-country study subject psoriatic arthritis ( PsA ) consist 2 part : Part 1 design compare achievement minimal disease activity ( MDA ) subject randomize either adalimumab combination methotrexate ( MTX ) MTX alone escalate high recommend tolerable dose ; Part 2 evaluate maintenance achievement MDA four different treatment regimen use adalimumab and/or MTX , subject allocation base initial randomized treatment achievement MDA Part 1 , rescue treatment option .</brief_summary>
	<brief_title>A Study Subjects With Psoriatic Arthritis Investigate Effectiveness Adalimumab Introduction Compared With Methotrexate Dose Escalation</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . PsA diagnosis establish least 4 week prior date Screening visit confirm ClASsification Psoriatic Arthritis ( CASPAR ) criteria 2 . Not MDA time screen 3 . Has 3 tender 3 swollen joint 4 . Treated methotrexate 15 mg ( weekly ) least 4 week 36 week 1 . Contraindications adalimumab therapy and/or know hypersensitivity adalimumab excipients 2 . History methotrexate intolerance/toxicity 3 . Medical condition ( ) preclude methotrexate dose increase 15 mg 4 . Had prior exposure tumor necrosis factor ( TNF ) inhibitor , mechanism action biologic DMARD ( bDMARD ) systemic biologic agent general</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
</DOC>